Investors

Our vision is to discover new, safe, and effective medications for treating neurological disorders.

Our mission is to develop novel proprietary small molecule to treat neuropathic pain.

Neuropathic pain resulting from diabetes or cancer is a widespread and debilitating condition affecting 5% of people and astonishing 25% of diabetics worldwide.
Current medications are not satisfactory due to poor efficacy or undesirable side effects.
Clear & convincing evidence that both sigma (σ1) and serotonin (5-HT7) receptors directly participate in the pain pathway.
Very profitable opportunity. Current market size is $2.4 Billion. Expected to grow to $7.5 Billion in 2020 in 7 major markets.

Daya’s innovative technology involves targeting both σ1 and 5-HT7 receptors with a single molecule to get an additive or synergistic effect.
The dual σ1/ 5-HT7 receptor strategy for developing pain medication represents a unique and pioneering concept that has not been disclosed by others.
Provisional patent application covering the composition of matter and use has been filed.

Proof of concept established. Daya has identified a new, proprietary, small molecule lead, DDD-028, which is orally active.
DDD-028 binds selectively to σ1 and 5-HT7 receptors with Ki’s of 220 nM and 195 nM respectively.
In off-target receptor profiling studies, DDD-028 shows no opioid activity.
In vivo, DDD-028 is effective in reversing neuropathic pain in mouse model at very low dose of 1.00 mg/kg.
DDD-028 is about 10-fold more potent than morphine and 180-fold more potent than gabapentin.

Conduct pharmacokinetic, ADME, bioavailability, and toxicity studies.
Evaluate DDD-028 in several neuropathic pain models: diabetic neuropathy, cancer pain, .
Optimize manufacturing process under GLP/GMP protocol.
File investigational new drug application (IND) with USFDA.